Literature DB >> 22498492

The TP53 tumor suppressor and autophagy in malignant lymphoma.

Zijun Y Xu-Monette1, Ken H Young.   

Abstract

The TP53 (p53) protein is a well-known tumor suppressor that plays a crucial role in maintaining genome stability under various cellular stresses. Loss of TP53 causes lymphomagenesis in mouse models and/or promotes tumor progression. However, the prognostic significance of TP53 has been inconsistent in human cancers including malignant lymphoma. In our recent review of TP53 dysfunction in lymphoid malignancies, we discussed the fact that the TP53 function in autophagy may be one of the important mechanisms responsible for the inconsistency of TP53 prognostic value, in that autophagy can promote survival of lymphoma cells by recycling toxic intracellular materials and inhibiting apoptosis. Here we discuss the biological mechanisms of TP53 functional switches from apoptosis to autophagy, and provide a brief summary of how TP53 regulates autophagy through its transcriptional activity on 14 genes of the TP53 pathway.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22498492      PMCID: PMC3378422          DOI: 10.4161/auto.19703

Source DB:  PubMed          Journal:  Autophagy        ISSN: 1554-8627            Impact factor:   16.016


  6 in total

1.  The p53 Mutation/Deletion Profile in a Small Cohort of the Omani Population with Diffuse Large B-Cell Lymphoma.

Authors:  Yahya Tamimi; Sheikha Al-Harthy; Ibrahim Al-Haddabi; Mohammed Al-Kindi; Hamza Babiker; Mansour Al-Moundhri; Ikram Burney
Journal:  Sultan Qaboos Univ Med J       Date:  2014-01-27

2.  Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.

Authors:  Zijun Y Xu-Monette; Lin Wu; Carlo Visco; Yu Chuan Tai; Alexander Tzankov; Wei-min Liu; Santiago Montes-Moreno; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; X Frank Zhao; William W L Choi; Xiaoying Zhao; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Fan Zhou; Brad S Kahl; Jane N Winter; Wei Xu; Jianyong Li; Ronald S Go; Yong Li; Miguel A Piris; Michael B Møller; Roberto N Miranda; Lynne V Abruzzo; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2012-09-05       Impact factor: 22.113

3.  HOXD3 Up-regulating KDM5C Promotes Malignant Progression of Diffuse Large B-Cell Lymphoma by Decreasing p53 Expression

Authors:  YuYing Cui; Chao Lv; Yu Wen; Dongmei Zhao; Yu Yang; Hongbin Qiu; Chennan Wang
Journal:  Balkan Med J       Date:  2021-12-20       Impact factor: 2.021

4.  TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy.

Authors:  Liting Chen; Wei Mu; Jia Gu; Min Xiao; Liang Huang; Miao Zheng; Chunrui Li; Yi Xiao; Jianfeng Zhou; Xiaolu Long
Journal:  Diagnostics (Basel)       Date:  2021-05-08

Review 5.  Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses.

Authors:  Joanna Obacz; Silvia Pastorekova; Borek Vojtesek; Roman Hrstka
Journal:  Mol Cancer       Date:  2013-08-14       Impact factor: 27.401

6.  cAMP-mediated autophagy inhibits DNA damage-induced death of leukemia cells independent of p53.

Authors:  Seham Skah; Nina Richartz; Eva Duthil; Karin M Gilljam; Christian Bindesbøll; Elin Hallan Naderi; Agnete B Eriksen; Ellen Ruud; Marta M Dirdal; Anne Simonsen; Heidi Kiil Blomhoff
Journal:  Oncotarget       Date:  2018-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.